Nandi J. Reddy
YOU?
Author Swipe
View article: Implementation of <i>DPYD</i> and <i>UGT1A1</i> Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial
Implementation of <i>DPYD</i> and <i>UGT1A1</i> Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial Open
PURPOSE To determine the feasibility and effectiveness of implementing pretreatment DPYD/UGT1A1 testing in patients with gastrointestinal cancer and its impact compared with a biobank population. MATERIALS AND METHODS A prospective, nonran…
View article: Magnetite Nanoparticle Development for Targeted Anti-Inflammatory Drug Delivery in Rheumatoid Arthritis
Magnetite Nanoparticle Development for Targeted Anti-Inflammatory Drug Delivery in Rheumatoid Arthritis Open
Introduction: About one percent of the world's population suffers with rheumatoid arthritis, a degenerative inflammatory disease that gradually destroys joints and causes severe pain and impairment. Because of their biocompatibility, contr…
View article: A Study on Stress Management Among Employess with Reference to Hetero Drug Ltd
A Study on Stress Management Among Employess with Reference to Hetero Drug Ltd Open
Stress is an all too a common part of life today.Sometimes few individuals can avoid.In fact, a nationwide survey conducted by a large life insurance company showed that nearly 46% of American workers believe their jobs are highly stressfu…
View article: Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing Open
Background Fluoropyrimidines (fluorouracil [5-FU], capecitabine) and irinotecan are commonly prescribed chemotherapy agents for gastrointestinal (GI) malignancies. Pharmacogenetic (PGx) testing for germline DPYD and UGT1A1 variants associa…
View article: 97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing Open
IMPACT: The implementation of DPYD and UGT1A1 pharmacogenetic testing, a promising tool of precision medicine, translates evidence-based research into clinical oncology practice with personalized dosing to better predict interpatient varia…
View article: <i>DPYD</i> and <i>UGT1A1</i> Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation
<i>DPYD</i> and <i>UGT1A1</i> Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation Open
Gastrointestinal (GI) malignancies are among the most commonly diagnosed cancers worldwide. Despite the introduction of targeted and immunotherapy agents in the treatment landscape, cytotoxic agents, such as fluoropyrimidines and irinoteca…